March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Morphological Characterization of Diabetic Macular Edema Responders and Non-Responders to Anti-VEGF Treatment using Spectral Domain OCT
Author Affiliations & Notes
  • Ana Rita Santos
    CEC,
    AIBILI, Coimbra, Portugal
  • Silvia Simão
    CEC,
    AIBILI, Coimbra, Portugal
  • Luísa Ribeiro
    CEC,
    AIBILI, Coimbra, Portugal
  • João Figueira
    CEC,
    AIBILI, Coimbra, Portugal
    Ophthalmology, Coimbra University Hospital, Coimbra, Portugal
  • Sandrina Nunes
    4C,
    AIBILI, Coimbra, Portugal
  • José Cunha-Vaz
    AIBILI, Coimbra, Portugal
  • Footnotes
    Commercial Relationships  Ana Rita Santos, None; Silvia Simão, None; Luísa Ribeiro, None; João Figueira, None; Sandrina Nunes, None; José Cunha-Vaz, Pfizer, Novartis, Alcon, Allergan (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 411. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ana Rita Santos, Silvia Simão, Luísa Ribeiro, João Figueira, Sandrina Nunes, José Cunha-Vaz; Morphological Characterization of Diabetic Macular Edema Responders and Non-Responders to Anti-VEGF Treatment using Spectral Domain OCT. Invest. Ophthalmol. Vis. Sci. 2012;53(14):411.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To characterize Diabetic Macular Edema (DME) morphological patterns in responders and non-responders to anti-VEGF treatment using Spectral Domain OCT (HD-CirrusTM).

Methods: : In a retrospective study, 20 patients with DME submitted to intravitreal injections of anti-VEGF Lucentis were selected according to their response to treatment after 6 months: 10 patients which had clear improvement of Best Corrected Visual Acuity (BCVA) (≥ 10 letters) and 10 patients with worsening or no improvement of BCVA. All patients performed BCVA measurements using ETDRS charts and HD-OCT at baseline, 3 and 6 months after initial injection. In each visit, the OCT scans were graded and classified in 5 types: type 1-diffuse DME without cystoid spaces, type 2-inner cystoid DME, type 3-outer cystoid DME, type 4-cystoid DME with cystoid spaces involving both inner and outer retina layers, and type 5-serous retinal detachment. Presence of epiretinal membrane (ERM) or retina traction was also evaluated. A decision and classification tree (CART) was used to identify OCT morphological patterns on both groups.

Results: : At baseline the group with good response to treatment presented the following patterns: 7 cases (70%) of DME type 1; 3 cases (30%) of DME type 2; 10 cases (100%) of DME type 3 and 5 cases (50%) of DME type 4, while the group with poor response to treatment presented 4 cases (40%) of DME type 1; 7 cases (70%) of type 2; 10 cases (100%) of type 3 and 7 cases (70%) of type 4. Poor response to treatment appears to be predominantly associated with type 2 and type 4 DME (70% of cases on both types vs 30% and 50%, respectively in the group with good response) while DME type 1 is more frequent in the group showing good response to treatment (70% of cases vs 40% in the group with poor response) (CART classification error ≤ 0,250). DME type 5 was only observed in 2 eyes of the good responders group. ERM and retina traction were observed in 3 and 1 eyes in each group and showed no change during the 6 months of treatment.

Conclusions: : Presence of cystoid spaces in the inner retina layers at baseline appears to be more frequent in non responders to treatment indicating that it may be a predictor of worse response to anti-VEGF treatment while diffuse macular edema without cystoid spaces appears to be associated with good response to anti-VEGF treatment. Assessment of morphological patterns of diabetic macular edema with OCT may give useful information about the expected outcome of anti-VEGF treatment.

Keywords: diabetic retinopathy • edema • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×